Skip to content

A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02028754
Acronym
RLOTUS
Enrollment
180
Registered
2014-01-07
Start date
2011-07-31
Completion date
2013-05-31
Last updated
2014-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Syndromes, Cataract

Brief summary

This study will evaluate the effect of sodium carboxymethylcellulose eye drops in the treatment of dry eye after cataract surgery.

Interventions

Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.

DRUGLevofloxacin

Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.

DRUGPrednisolone

Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.

Sponsors

Allergan
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of age-related cataract in the study eye * Scheduled for cataract surgery and lens implant

Exclusion criteria

* Diagnosis of ocular surface disease or glaucoma * Ocular surgery in the past 3 months * Wearing a corneal contact lens in the study eye

Design outcomes

Primary

MeasureTime frameDescription
Tear Break-Up Time (TBUT) in the Study EyeDay 7TBUT is the time required for dry spots to appear on the surface of the study eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film.

Secondary

MeasureTime frameDescription
Fluorescein Staining Score in the Study EyeDay 7, Day 30The cornea is evaluated following ocular administration of fluorescein stain in the study eye. The cornea is the transparent front part of the eye which covers the iris and pupil. The cornea is divided into 3 regions. Each region is scored according to the extent of staining, with scores ranging from 0 to 3 points: 0=non-staining, 1=staining range \< 1/2 of the cornea, 2=staining range ≥ 1/2 of the cornea, and 3=regional whole staining of the cornea. The total score ranges from 0 to 9 points. The higher the staining score, the worse the dry eye condition.
Lissamine Green Staining Score in the Study EyeDay 7, Day 30Conjunctival and corneal staining are evaluated following ocular administration of lissamine green dye in the study eye. The conjunctiva is the clear membrane covering the white surface of the eye. The cornea is the transparent front part of the eye which covers the iris and pupil. The conjunctiva and cornea are divided into 5 regions that are scored based on the extent of staining. Scores range from 0 to 3 points: 0=non-staining, 1=staining range \< 1/2 of the conjunctiva and cornea, 2=staining range ≥ 1/2 of the conjunctiva and cornea, and 3=regional whole staining of the conjunctiva and cornea. The total score ranges from 0 to 15 points. The higher the grade score, the worse the dry eye condition.
Results of Schirmer I Test With Anesthetics in the Study EyeDay 7, Day 30The Schirmer I test consists of anesthetic drops being placed into the lower eyelid of the study eye. Patients then close their eyes. Test paper is placed on the lower eyelid of the patient's closed eyes. The paper is then removed and the moisture length on the paper recorded. Shorter distances indicate worse dry eye symptoms.
Ocular Surface Disease Index (OSDI) Questionnaire Score in the Study EyeDay 7, Day 30The OSDI is a 12-question survey for patients to document their dry eye disease symptoms in the study eye. The OSDI consists of a 5-point scale (0=none of the time and 4 = all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability).
Subjective Symptom Total Score in the Study EyeDay 7, Day 30The following 11 subjective symptoms are evaluated in the study eye: foreign body sensation, photophobia, itching, pain in the eye, dry eye, eye heaviness, blurred vision, eye fatigue, eye discomfort, eye secretions and tears. Each of these symptoms is divided into 4 classes: no symptom=0; occasional symptoms=1; intermittent mild symptoms=2; and persistent obvious symptoms=3. The total score ranged from 0 (best) to 33 (worst).

Countries

China

Participant flow

Participants by arm

ArmCount
Sodium Carboxymethylcellulose and Conventional Therapy
Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days plus conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
90
Conventional Therapy
Conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
90
Total180

Baseline characteristics

CharacteristicSodium Carboxymethylcellulose and Conventional TherapyConventional TherapyTotal
Age, Continuous68.8 Years
STANDARD_DEVIATION 7.1
69.0 Years
STANDARD_DEVIATION 7.1
68.9 Years
STANDARD_DEVIATION 7.1
Sex: Female, Male
Female
54 Participants59 Participants113 Participants
Sex: Female, Male
Male
36 Participants31 Participants67 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 860 / 85
serious
Total, serious adverse events
0 / 860 / 85

Outcome results

Primary

Tear Break-Up Time (TBUT) in the Study Eye

TBUT is the time required for dry spots to appear on the surface of the study eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film.

Time frame: Day 7

Population: All patients with data at this time point

ArmMeasureValue (MEAN)Dispersion
Sodium Carboxymethylcellulose and Conventional TherapyTear Break-Up Time (TBUT) in the Study Eye8.5 SecondsStandard Deviation 5.5
Conventional TherapyTear Break-Up Time (TBUT) in the Study Eye6.6 SecondsStandard Deviation 3.8
Primary

Tear Break-Up Time (TBUT) in the Study Eye

TBUT is the time required for dry spots to appear on the surface of the study eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film.

Time frame: Day 30

Population: All patients with data at this time point

ArmMeasureValue (MEAN)Dispersion
Sodium Carboxymethylcellulose and Conventional TherapyTear Break-Up Time (TBUT) in the Study Eye9.0 SecondsStandard Deviation 5.9
Conventional TherapyTear Break-Up Time (TBUT) in the Study Eye6.7 SecondsStandard Deviation 4.8
Secondary

Fluorescein Staining Score in the Study Eye

The cornea is evaluated following ocular administration of fluorescein stain in the study eye. The cornea is the transparent front part of the eye which covers the iris and pupil. The cornea is divided into 3 regions. Each region is scored according to the extent of staining, with scores ranging from 0 to 3 points: 0=non-staining, 1=staining range \< 1/2 of the cornea, 2=staining range ≥ 1/2 of the cornea, and 3=regional whole staining of the cornea. The total score ranges from 0 to 9 points. The higher the staining score, the worse the dry eye condition.

Time frame: Day 7, Day 30

Population: All patients with data at this time point

ArmMeasureGroupValue (MEAN)Dispersion
Sodium Carboxymethylcellulose and Conventional TherapyFluorescein Staining Score in the Study EyeDay 72.0 Scores on a ScaleStandard Deviation 2.8
Sodium Carboxymethylcellulose and Conventional TherapyFluorescein Staining Score in the Study EyeDay 30 (N=83, 82)1.1 Scores on a ScaleStandard Deviation 1.8
Conventional TherapyFluorescein Staining Score in the Study EyeDay 71.8 Scores on a ScaleStandard Deviation 2.6
Conventional TherapyFluorescein Staining Score in the Study EyeDay 30 (N=83, 82)1.2 Scores on a ScaleStandard Deviation 1.9
Secondary

Lissamine Green Staining Score in the Study Eye

Conjunctival and corneal staining are evaluated following ocular administration of lissamine green dye in the study eye. The conjunctiva is the clear membrane covering the white surface of the eye. The cornea is the transparent front part of the eye which covers the iris and pupil. The conjunctiva and cornea are divided into 5 regions that are scored based on the extent of staining. Scores range from 0 to 3 points: 0=non-staining, 1=staining range \< 1/2 of the conjunctiva and cornea, 2=staining range ≥ 1/2 of the conjunctiva and cornea, and 3=regional whole staining of the conjunctiva and cornea. The total score ranges from 0 to 15 points. The higher the grade score, the worse the dry eye condition.

Time frame: Day 7, Day 30

Population: All patients with data at this time point

ArmMeasureGroupValue (MEAN)Dispersion
Sodium Carboxymethylcellulose and Conventional TherapyLissamine Green Staining Score in the Study EyeDay 72.9 Scores on a ScaleStandard Deviation 3.3
Sodium Carboxymethylcellulose and Conventional TherapyLissamine Green Staining Score in the Study EyeDay 30 (N=83,82)2.1 Scores on a ScaleStandard Deviation 2.4
Conventional TherapyLissamine Green Staining Score in the Study EyeDay 30 (N=83,82)2.3 Scores on a ScaleStandard Deviation 2.6
Conventional TherapyLissamine Green Staining Score in the Study EyeDay 72.6 Scores on a ScaleStandard Deviation 3.2
Secondary

Ocular Surface Disease Index (OSDI) Questionnaire Score in the Study Eye

The OSDI is a 12-question survey for patients to document their dry eye disease symptoms in the study eye. The OSDI consists of a 5-point scale (0=none of the time and 4 = all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability).

Time frame: Day 7, Day 30

Population: All patients with data at this time point

ArmMeasureGroupValue (MEAN)Dispersion
Sodium Carboxymethylcellulose and Conventional TherapyOcular Surface Disease Index (OSDI) Questionnaire Score in the Study EyeDay 30 (N=83, 82)12.7 Scores on a ScaleStandard Deviation 11.3
Sodium Carboxymethylcellulose and Conventional TherapyOcular Surface Disease Index (OSDI) Questionnaire Score in the Study EyeDay 715.6 Scores on a ScaleStandard Deviation 16.8
Conventional TherapyOcular Surface Disease Index (OSDI) Questionnaire Score in the Study EyeDay 30 (N=83, 82)14.2 Scores on a ScaleStandard Deviation 13.8
Conventional TherapyOcular Surface Disease Index (OSDI) Questionnaire Score in the Study EyeDay 718.1 Scores on a ScaleStandard Deviation 19.5
Secondary

Results of Schirmer I Test With Anesthetics in the Study Eye

The Schirmer I test consists of anesthetic drops being placed into the lower eyelid of the study eye. Patients then close their eyes. Test paper is placed on the lower eyelid of the patient's closed eyes. The paper is then removed and the moisture length on the paper recorded. Shorter distances indicate worse dry eye symptoms.

Time frame: Day 7, Day 30

Population: All patients with data at this time point

ArmMeasureGroupValue (MEAN)Dispersion
Sodium Carboxymethylcellulose and Conventional TherapyResults of Schirmer I Test With Anesthetics in the Study EyeDay 30 (N=83, 82)12.7 MillimetersStandard Deviation 6.1
Sodium Carboxymethylcellulose and Conventional TherapyResults of Schirmer I Test With Anesthetics in the Study EyeDay 711.8 MillimetersStandard Deviation 5.6
Conventional TherapyResults of Schirmer I Test With Anesthetics in the Study EyeDay 712.5 MillimetersStandard Deviation 6.8
Conventional TherapyResults of Schirmer I Test With Anesthetics in the Study EyeDay 30 (N=83, 82)12.6 MillimetersStandard Deviation 6.5
Secondary

Subjective Symptom Total Score in the Study Eye

The following 11 subjective symptoms are evaluated in the study eye: foreign body sensation, photophobia, itching, pain in the eye, dry eye, eye heaviness, blurred vision, eye fatigue, eye discomfort, eye secretions and tears. Each of these symptoms is divided into 4 classes: no symptom=0; occasional symptoms=1; intermittent mild symptoms=2; and persistent obvious symptoms=3. The total score ranged from 0 (best) to 33 (worst).

Time frame: Day 7, Day 30

Population: All patients with data at this time point

ArmMeasureGroupValue (MEAN)Dispersion
Sodium Carboxymethylcellulose and Conventional TherapySubjective Symptom Total Score in the Study EyeDay 76.1 Scores on a ScaleStandard Deviation 5.3
Sodium Carboxymethylcellulose and Conventional TherapySubjective Symptom Total Score in the Study EyeDay 30 (N=83, 82)5.1 Scores on a ScaleStandard Deviation 3.6
Conventional TherapySubjective Symptom Total Score in the Study EyeDay 76.4 Scores on a ScaleStandard Deviation 5.2
Conventional TherapySubjective Symptom Total Score in the Study EyeDay 30 (N=83, 82)5.6 Scores on a ScaleStandard Deviation 4

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026